EECCTM 2027 works with selected organisations whose activities align with the priorities of clinical and translational medicine, including research advancement, clinical innovation, implementation, evidence generation, and strategic healthcare collaboration. Partnerships are designed to support relevant exchange, executive engagement, and meaningful visibility within a focused congress environment.
The categories below indicate the kinds of organisations that may collaborate with the congress.
Clinical partners enabling real-world pathways for translation, implementation, and outcomes measurement.
Typical partners include hospital networks, specialty centres, clinical operations teams, and quality or safety functions supporting measurable care improvements and responsible adoption.
Organisations shaping frameworks for safe, effective, and compliant clinical translation and evaluation.
This may include standards organisations, health technology assessment groups, ethics or oversight bodies, and public agencies supporting evidence generation, transparency, and adoption readiness.
Industry partners supporting translational pipelines, clinical development, and outcome-driven innovation.
Includes R&D organisations, clinical operations, medical affairs, HEOR and real-world evidence teams, and partnerships focused on ethical, patient-centred translation from evidence to practice.
Organisations supporting research-to-practice translation across clinical and translational medicine.
Includes translational research institutes, clinical trial units, implementation science groups, and methodologists contributing frameworks, evaluation methods, and scalable adoption insights.
Associations enabling cross-specialty exchange and implementation of best-practice translational models.
May include medical societies, nursing and allied health bodies, and quality or safety associations bringing frontline perspectives and practical adoption challenges.
Entities supporting scale-up of validated translational solutions and outcome-driven programs.
Includes innovation hubs, accelerators, and strategic investors focused on adoption maturity, clinical validation, and implementation quality across care pathways.
Strategic collaborations are reviewed based on alignment with clinical translation, real-world evidence, implementation, and outcome-driven healthcare innovation.
